Glioblastoma (GBM) is the most aggressive and lethal form of brain cancer, with a median survival of only 15 months despite intensive treatment. Current therapies—including surgery, radiation, and chemotherapy—offer limited ...
Jun 11, 2025
0
14
In patients with an aggressive form of breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus pembrolizumab resulted in durable responses with improved progression free survival compared to the ...
Jun 2, 2025
0
31
A study by researchers from Johns Hopkins Medicine, the Johns Hopkins Bloomberg School of Public Health and The Johns Hopkins University Whiting School of Engineering finds that neutrophils—the most abundant type of white ...
May 22, 2025
0
172
Pembrolizumab (Keytruda) given before and after surgery to supplement adjuvant therapy improved responses and survival in patients with previously untreated, locally advanced head and neck squamous cell carcinoma (HNSCC), ...
Apr 29, 2025
0
14
Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without the cancer coming back ...
Apr 28, 2025
0
15
Thymic epithelial tumors are a rare group of malignancies originating in the thymus gland, that includes thymoma and thymic carcinoma. Among these, thymic carcinoma is the more aggressive subtype, characterized by high invasiveness, ...
Mar 12, 2025
0
12
Researchers from the University of Chicago Medicine Comprehensive Cancer Center have demonstrated the potential of a novel treatment approach including immunotherapy to treat advanced human papillomavirus (HPV)-negative head ...
Mar 6, 2025
0
17
Triple-negative breast cancer (TNBC) is an aggressive form of the disease that accounts for 15% of all breast cancer cases. Black women are twice as likely as white women to be diagnosed with TNBC and 28% more likely to die ...
Feb 18, 2025
0
15
Researchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at the Peter Doherty Institute of Infection and Immunity (Doherty Institute), in collaboration with Pfizer, ...
Feb 12, 2025
0
20
A Peter Mac-led international clinical trial has shown adding an immunotherapy drug to the chemotherapy that patients receive ahead of surgery can dramatically improve breast cancer cure rates.
Jan 28, 2025
0
46
